Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165983 · ClinicalTrials.gov registry record · NA
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
NCT01165983: Completed NA study, sponsored by Beth Israel Deaconess Medical Center.
NCT01165983 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 124 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01165983, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.
Primary Outcome
Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.
Interventions
- DRUG Placebo
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-11 |
| Phase | NA |
What the finished NCT01165983 record still lists
NCT01165983 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01165983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01165983 about?
NCT01165983 is a clinical study titled "The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes". The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.
What is the current status of trial NCT01165983?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01165983?
The interventions under investigation include: Placebo (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT01165983?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01165983's enrollment target sits among peer trials
124 758th of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia